National Institute of Allergy and Infectious Diseases
Link to NIAID Home Page Link to NIAID Home Page Link to NIH Home Page
NIAID Home Health & Science Research Funding Research News & Events Labs at NIAID About NIAID

Radiation Countermeasures
 Program
  Introduction
  Scientific Background
  Strategic Planning
  Basic and Translational Goals
  Focused Product Goals
  Infrastructure Goals
  Radiation Biodosimetry Goals
 Research Areas
 Resources
 Funding
 Summaries and Publications
 Congressional Testimonies


Medical Countermeasures Against Radiological and Nuclear Threats

Basic and Translational Research Goals

NIH Goals for Basic and Translational Research

Immediate Goals

  • Understand the effects of different levels of radiation exposure, with special emphasis on the moderate dose range
  • Define the mechanisms of radiation injury, including secondary responses and multi-system injury
  • Determine mechanisms of protection, mitigation, and treatment
  • Identify appropriate hierarchical animal models

Long-Term Goals

  • Understand radiation injury at the molecular and cellular level, including the role of inflammation, neuroimmune interactions, endothelial injury, and other factors that influence the pathophysiological manifestations of radiation injury
  • Identify new drug candidates and accelerate the transition from candidate to product
  • Continue to support research on long-term effects of radiation exposure, including epidemiological and longitudinal medical studies of individuals exposed to radiation

Current Status of Basic and Translational Research

The creation and acquisition of new and effective medical countermeasures for radiation injuries among the civilian population will require basic research to expand the knowledge base, as well as translational research to begin the transformation of fundamental knowledge gained into product development. Fortunately, a significant research base already exists. The Department of Defense (DOD) has had a longstanding interest in the health effects of ionizing radiation on military personnel, and has sought ways to protect its forces from radiation and radioactive material released by nuclear weapons; however, funding for these research efforts has declined since the end of the Cold War. Several civilian government agencies support longitudinal epidemiologic studies to assess long-term health risks to X-ray technicians exposed to low-dose radiation, civilians exposed to nuclear weapons test fallout, survivors of Hiroshima and Nagasaki, and subpopulations near Chernobyl, Ukraine. These studies will provide essential knowledge for the long-term followup of individuals who are exposed to radiation as the result of a terrorist incident. NIAID, the National Cancer Institute (NCI), and other agencies within HHS currently support research on the molecular and cellular aspects of low- and moderate-dose radiation exposure. Although this research has focused largely on therapeutic uses of ionizing radiation, the results and programs can be adapted to the development of countermeasures.

Research Agenda for Basic and Translational Research

NIH established a research centers program called Centers for Medical Countermeasures Against Radiation that will serve as a network of specialized research institutions working collaboratively to meet the goals of the NIH Strategic Plan and Research Agenda for Medical Countermeasures Against Radiological and Nuclear Threats in basic and translational research. Examples of research areas to be addressed include

  • Innate and adaptive immune system enhancement and reconstitution
  • Mechanisms of radiation injury and therapy at the systemic, organ, cell, and molecular levels; and identification and verification of potential targets for countermeasures for radiation injury
  • Mechanisms of secondary responses that mediate, exacerbate, or ameliorate damage and disease resulting from external or internal radiation exposure in different tissues
  • Long-term effects, such as cancer and fibrosis
  • New animal models and in vitro assays to test and evaluate promising countermeasures

back to top

Highlights

RFA-DK-08-010: Intestinal Stem Cell Consortium (U01) - Co-Funded by the NIAID Radiation/Nuclear Program.  Receipt date: March 18, 2009.

Pre-Solicitation Notice issued by BARDA, HHS, January 16, 2009: Advanced Therapeutics for Treating Neutropenia Resulting from Acute Exposure to Ionizing Radiation

Presolicitation Notice Issued by BARDA, HHS, January 16, 2009: Point of Care of High-Throughput Biological Assays for Determining Absorbed Ionizing Radiation Dose (Biodosimetry) after Radiologic and Nuclear Events.

See Also

  • Radiological and Nuclear Threats News Releases
  • Division of Allergy, Immunology, and Transplantation (DAIT)
  • Biodefense—The NIAID Biodefense Web site includes biodefense-related information for biomedical researchers, the public, and the media.
  • E-mail Icon E-mail this page
    Print Icon Print this page

    Highlights

    RFA-DK-08-010: Intestinal Stem Cell Consortium (U01) - Co-Funded by the NIAID Radiation/Nuclear Program.  Receipt date: March 18, 2009.

    Pre-Solicitation Notice issued by BARDA, HHS, January 16, 2009: Advanced Therapeutics for Treating Neutropenia Resulting from Acute Exposure to Ionizing Radiation

    Presolicitation Notice Issued by BARDA, HHS, January 16, 2009: Point of Care of High-Throughput Biological Assays for Determining Absorbed Ionizing Radiation Dose (Biodosimetry) after Radiologic and Nuclear Events.

    See Also

  • Radiological and Nuclear Threats News Releases
  • Division of Allergy, Immunology, and Transplantation (DAIT)
  • Biodefense—The NIAID Biodefense Web site includes biodefense-related information for biomedical researchers, the public, and the media.